---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-23-000022"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:41:35.187115+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q1 net loss $13.6M; positive Phase 1 data for IMM-1-104 accelerates timeline

## Summary
- Net loss $13.6M ($0.51/sh) for Q1 2023; cash & equivalents $91.5M as of Mar 31, 2023.
- Positive initial Phase 1 PK, PD, safety data for IMM-1-104: significant PK Cmax, ~2h half-life, no DLTs.
- RP2D expected early 2024 (accelerated); potential to assess preliminary efficacy sooner than anticipated.
- Completed $30M stock offering (2.73M shares at $11.00); cash runway extended into 2025.
- Appointed Harold E. Brakewood as CBO in March 2023; IND for IMM-6-415 expected Q4 2023.

## SEC filing metadata
- accession: 0001790340-23-000022
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034023000022/0001790340-23-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034023000022/imrx-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-23-000022
- JSON: https://secwatch.observer/filing/0001790340-23-000022.json
- Plain text: https://secwatch.observer/filing/0001790340-23-000022.txt

## Key facts
- Earnings Releases
  Immuneering Corp reported the first quarter ended March 31, 2023 results: net income $13.6 million, EPS $0.51 per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: $13.6 million
  - EPS: $0.51 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders was $13.6 million, or $0.51 per share, for the first quarter ended March 31, 2023, compared to $12.9 million, or $0.49 per share, for the first quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000179034023000022/0001790340-23-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.